



## **89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference**

September 5, 2023

SAN FRANCISCO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference, being held in New York, NY on Monday, September 11, 2023 at 7:00 AM ET.

The webcast of the fireside chat will be accessible [here](#) and in the investor section of [89bio's website](#).

### **About 89bio**

89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit [www.89bio.com](http://www.89bio.com) or follow the company on [LinkedIn](#).

### **Investor Contact:**

Ryan Martins  
Chief Financial Officer  
[investors@89bio.com](mailto:investors@89bio.com)

PJ Kelleher  
LifeSci Advisors, LLC  
+1-617-430-7579  
[pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)

### **Media Contact:**

Sheryl Seapy  
Real Chemistry  
[sseapy@realchemistry.com](mailto:sseapy@realchemistry.com)